CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $1.48M rose 53.5% year over year, ahead of the -2.2% change in trailing-twelve-month other income / expenses. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +37.4% a year.
Context
- Other income / expenses amounted to 6.9% of revenue in FY2025, up 1.7 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +53.5% holds above the trailing-twelve-month pace of -2.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 5.23M USD
- Year-over-year change
- -26.3%
- 4-year CAGR
- +134.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.23M | -26.3% |
| FY2024 | 2024-12-31 | 7.1M | -27.6% |
| FY2023 | 2023-12-31 | 9.81M | +386.0% |
| FY2022 | 2022-12-31 | 2.02M | +1073.3% |
| FY2021 | 2021-12-31 | 172K | — |
Other Income / Expenses vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 other income / expenses of $5.75M is the 4th highest of the 10 companies compared; the peer median is $4.52M.
- Its year-over-year change of -2.2% is the 3rd highest of 9, against a peer median of -30.6%.
- Other income / expenses amounts to 16.2% of revenue for CTMX, versus a peer median of 38.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.23M | +206.4% | +46.5% | 52.6% | |
| LTM Sep 2026 | $25.39M | -19.9% | +114.2% | 22670.5% | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Mar 2026 | $5.75M | -2.2% | +37.4% | 16.2% | |
| LTM Mar 2026 | $5.52M | -41.1% | +30.8% | 39.8% | |
| LTM Jun 2024 | $4.52M | — | -7.1% | 554.5% | |
| LTM Sep 2026 | -$4.02M | -127.7% | +39.5% | 1.5% | |
| LTM Mar 2026 | -$7.37M | -116.5% | — | 4.7% | |
| LTM Mar 2026 | -$17.66M | +27.0% | — | 22.3% | |
| LTM Mar 2026 | -$38.64M | -613.7% | — | 38.8% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $4.52M | -30.6% | +43.0% | 38.8% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.